Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment

摘要

Secukinumab, anti-interleukin (IL)-17A, is a new agent for treating spondyloarthritis. Some cases of new-onset or flare of inflammatory bowel disease (IBD) during secukinumab treatment have been reported.[ - ] In this article, we present a case of new-onset IBD following secukinumab treatment.